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Objective:  To investigate the potential effect of smoking on pathological staging in clinically low-risk
patients.
Subjects and  methods:  Data of 59 patients who were diagnosed with a bladder tumor for the first time and
had a single lesion radiologically and endoscopically smaller than 3 cm were investigated, retrospectively.
A total of 33 patients who currently smoke or smoked were classified as Group I and 26 patients who did
not ever smoke were classified as Group II. Pathological diagnoses of the patients in both groups were
compared.
Results: A total of 9 patients (27.3%) in Group I and 18 patients (69.2%) in Group II had Ta disease
(p < 0.05). Moreover, 19 patients (57.6%) in Group I and 5 patients (19.2%) in Group II had stage T1
disease (p < 0.05). The number of patients with low grade (LG) tumor were 8 (24.2%) and 19 (73.1%) in
Group I and in Group II, respectively (p < 0.05). The number of patients with high grade (HG) tumor were
25 (75.8%) and 7 (26.9%) in Group I and in Group II, respectively (p < 0.05). Ta high grade (TaHG) was
detected in 9 (27.3%) patients in Group I. In contrast, no patients in Group II had Ta HG disease (p < 0.05).
The number of patients with T1 high grade (T1HG) was 17 (51.5%) in Group I and 2 (7.69%) in Group II
(p < 0.05).
Conclusion:  Smoking seems to associate with pathologically worse stage and grade in patients with primary,
single, <3 cm bladder cancer.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open
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ntroduction
ladder cancer is the ninth most frequently-diagnosed cancer
orldwide [1]. In bladder cancer, male/female ratio is 3.5:1
orldwide [2]. Association of the smoking habit with a bladder
umor has been well known. Smoking is the worst risk factor for
nd hosting by Elsevier B.V. This is an open access article under the CC
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Table  1  The differences between groups in terms of age values
and gender frequency.
Group I (n = 33) Group II (n = 26) p
Age (years) 69.5 (55.8–75.3) 66.0 (57.0–73.0) =0.427*












































Effect of smoking on pathological grade and stage in clinically 
bladder cancer and increases the risk of bladder cancer by 2–4
times [3]. The pathological stage and grade of the tumor determined
by histopathological examination are important prognostic factors
that determine the number and diameter of the tumor, prior recur-
rence rate, and carcinoma in situ for bladder cancer [4,5]. Bladder
cancer in patients who smoke and have a non-muscle-invasive
disease is associated with an advanced tumor stage and grade [6].
However, the studies investigating the effect of smoking on the
stage and grade in clinically low-risk patients with bladder tumors
that are smaller than 3 cm are limited. The aim of the present study
was to study the effect of cigarette smoking on pathological staging
in patients with clinically low-risk bladder cancer.
Subjects  and  methods
The files of 154 patients who were diagnosed with bladder can-
cer for the first time between 2009 and 2013 were retrospectively
reviewed. Among them, 59 first-time patients with a single lesion
that was radiologically and endoscopically <3 cm in diameter
were finally included in the study. European Association of Urol-
ogy (EAU) guidelines for non-muscle invasive bladder cancer
divided patients into risk groups. According to these data we
consider as clinically low-risk patients the ones that have the pri-
mary and solitary tumors, <3 cm, and no carcinoma in situ (CIS)
characteristics [5,7]. Patients who were diagnosed with carcinoma
in situ (CIS) in pathology specimens were excluded.
The age at first diagnosis, smoking status, stage, grade of the primary
tumor, and tumor diameter and number were evaluated. Patients who
had no data on the records about smoking habits were excluded
from the study. Patients who actively smoke cigarettes or former
smokers were designated as Group I and lifetime non-smokers were
designated as Group II. Group I consisted of 33 patients and Group
II had 26 patients. Pathological diagnoses of the patients in both
groups were compared.
The grading of the samples was performed according to the World
Health Organization (WHO) system in 2004 and the staging was
performed according to TNM classification approved by the Union
International Contre le Cancer (UICC) in 2009.
All procedures performed in studies involving human participants
were in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki Dec-
laration and its later amendments or comparable ethical standards.
Statistical  analysis
Data obtained in this study were analyzed using the SPSS 20 (IBM
SPSS Statistics; Armonk, NY, USA) package program. Continuous
variables with non-Gaussian distribution were presented as a median
(25th and 75th percentiles). Statistical comparisons of two groups
were performed with the Mann–Whitney U test for data with a non-
Gaussian distribution. Pearson’s chi-square test and Fisher’s exact
test were used to compare categorical variables. Logistic regression
analysis was used when the independent variables include nominal
measures and the outcome variable was binary. This analysis was
also used to interpret odds ratios with 95% confidence intervals. The





* p value calculated by Mann–Whitney U Test.
** p value calculated by Fisher’s exact test.
esults
pidemiologic and pathologic data are displayed in Tables 1 and 2.
he number of patients with the pathologic stage Ta was 9 (27.3%)
n Group I and 18 (69.2%) in Group II (p = 0.003). In the Group
I, the rate of detection of the Ta tumor was significantly higher
hile the rate of detection of the T1 tumor was significantly higher
n Group I (p = 0.007). Pathological T2 tumor rates were equally
istributed in both groups (p = 1). The number of patients with a
G tumor was 8 (24.2%) in Group I and 19 (73.1%) in Group II
p < 0.05). The number of patients with a HG tumor was 25 (75.8%)
nd 7 (26.9%) in Group I and Group II respectively (p < 0.05). It was
ound that cigarette smoking associates with a higher tumor grade.
hen the pathological grade and stage distributions of the groups
ere evaluated together, the number of Ta LG patients was 11
33.3%) and 15 (57.7%) in Group I and Group II, respectively. There
ere 9 Ta HG patients (27.3%) in Group I and zero Group II. Smok-
ng was not associated with a LG pathological stage (p = 0.108) and
t was found to increase the risk of Ta HG (p < 0.05). The number
f patients with T1 HG tumors were 17 (51.5%) in Group I and
 (7.69%) patients in Group II (p < 0.05). We found that smoking
as associated with a HG in Ta and T1 stage tumors. It was deter-
ined that the association of smoking with the tumor stage and grade
n muscle-invasive bladder tumors was similar to that of Group II
p = 1) (Table 2).
iscussion
ccupational exposure to aromatic amines, polycyclic aromatic
ydrocarbons, and chlorinated hydrocarbons and smoking are two
mportant risk factors for developing bladder cancer. Tobacco con-
ains more than 60 carcinogens including benzidine derivatives
nd aromatic amines. These substances have an important role in
eveloping bladder cancer. In addition, studies have shown that high-
rade bladder tumors develop more often in people with high-risk
ccupations such as industrial plants, which process dye, paint, met-
ls, and petroleum products [8–10]. Moreover, cigarette smoking
ncreases the risk of recurrence and progression of non-muscle-
nvasive bladder cancer (NMIBC) [11]. The association of cigarette
moking with bladder cancer has been known for 60 years and
ccounts for about 50% of cases [12].
wo main mutation pathways are responsible for bladder can-
er development. One of these is the fibroblast growth factor
eceptor-3 (FBFR-3) mutation, which is significantly associated
ith lower grade tumor development [13]. The other mutation
s related to the p53-oncogene and associated with the devel-
pment of high grade tumors. Smoking is associated with the
evelopment of higher grades of bladder cancer and causes this
hrough mutations in both pathways. Therefore, the prevalence
f aggressive tumors in smokers is higher than in non-smokers.
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Table  2  The relationship between the groups and the variables of the chi-square test results and the odds ratios interpreted by logistic regression
analysis.
Group I Group II Total p Odds ratio (95% CI)
n (%) n (%) n (%)
Ta Absent 24 (72.7%) 8 (30.8%) 32 (54.2%) 0.003* 0.17 (0.06–0.52)
Exist 9 (27.3%) 18 (69.2%) 27 (45.8%)
Total 33 (100%) 26 (100%) 59 (100%)
T1 Absent 14 (42.4%) 21 (80.8%) 35 (59.3%) 0.007* 5.70 (1.73–18.80)
Exist 19 (57.6%) 5 (19.2%) 24 (40.7%)
Total 33 (100%) 26 (100%) 59 (100%)
T2 Absent 28 (84.9%) 23 (88.5%) 51 (86.4%) 1** 1.37 (0.29–6.25)
Exist 5 (15.2%) 3 (11.5%) 8 (13.6%)
Total 33 (100%) 26 (100%) 59 (100%)
Grade LG 8 (24.2%) 19 (73.1%) 27 (45.8%) 0.001* 8.48 (2.62–27.52)
HG 25 (75.8%) 7 (26.9%) 32 (54.2%)
Total 33 (100%) 26 (100%) 59 (100%)
Ta LG Absent 22 (66.7%) 11 (42.3%) 33 (55.9%) 0.108* 0.37 (0.13–1.06)
Exist 11 (33.3%) 15 (57.7%) 26 (44.1%)
Total 33 (100%) 26 (100%) 59 (100%)
Ta HG Absent 24 (72.7%) 26 (100%) 50 (84.7%) 0.003** 0
Exist 9 (27.3%) 0 (0%) 9 (15.3%)
Total 33 (100%) 26 (100%) 59 (100%)
T1 LG Absent 31 (93.9%) 23 (88.5%) 54 (91.5%) 0.646** 0.50 (0.08–3.21)
Exist 2 (6.1%) 3 (11.5%) 5 (8.5%)
Total 33 (100%) 26 (100%) 59 (100%)
T1 HG Absent 16 (48.5%) 24 (92.3%) 40 (67.8%) 0.001** 12.82 (2.58–62.50)
Exist 17 (51.5%) 2 (7.7%) 19 (32.2%)
Total 33 (100%) 26 (100%) 59 (100%)
T2 LG Absent 32 (97.0%) 25 (96,2%) 57 (96.6%) 1** 0.78 (0.05–13.16)
Exist 1 (3.0%) 1 (3.9%) 2 (3.4%)
Total 33 (100%) 26 (100%) 59 (100%)
T2 HG Absent 29 (87,9%) 23 (88.5%) 52 (88.1%) 1** 1.04 (0.21–5.26)
Exist 4 (12.1%) 3 (11.5%) 7 (11.9%)














































LG: low grade, HG: high grade, CI, confidence interval.
* p value calculated by Pearson’s chi-square test.
** p value calculated by Fisher’s exact test.
n a study published recently, the rate of high grade tumors in
mokers was 26% and in non-smokers was 13%. This differ-
nce was statistically significant (p < 0.05) [13]. In our study,
he prevelance of high grade bladder cancer was significantly
igher in patients who smoked than in never smokers (91% vs.
.7%).
ge and gender are important risk factors for bladder cancer. Blad-
er cancer is detected more often in men. However, in women
he prognosis is worse. Women who smoke have shown an
ncreased risk of invasive bladder cancer when compared to men
ho smoke [14]. Bladder cancer affects people of middle and
dvanced ages. Approximately 90% of initially diagnosed blad-
er cancer patients are >60 years of age. Bladder cancer under
5 years of age is rare. Sturgeon et al. [15] showed that
igarette smoking increased the risk of muscle-invasive tumors
n patients younger than 60 years. There was no statistically
ignificant relationship between smoking and the stage of the
umor in patients >60 years old or older. The average age of
ur study was 66.4 years and 62.7 years in the ever smoker
nd never smoker groups, respectively. We did not detect any
orrelation between muscle-invasive tumors and cigarette smok-
ng, which may be because there were no female patients





he relationship between cigarette smoking and the stage of the
umor at the initial diagnosis differs in various studies. Although
ome studies have reported that cigarette smoking does not affect the
tage and grade of the tumor, some other studies have reported that
igarette smoking is associated with high grade tumors and some
tudies found that cigarette smoking is associated with low grade
umors [14–18]. In a recent study, Jiang et al. [14] reported that
he incidence of advanced stage bladder tumors especially muscle-
nvasive bladder tumors was higher in smokers. The same study also
eported that, as smoking duration and smoking intensity increased,
igh grade tumors and muscle-invasive tumors were detected at
wice the rate than low grade tumors. Nevertheless, Sturgeon et al.
15] investigated the relationship between cigarette smoking and
he grade of the bladder tumor. They found that smoking was
trongly associated with low-grade bladder cancer. The authors did
ot explain the cause of this result.
egarding tumor size, Fleshner et al. [16] reported that smoking
id not affect the tumor grade and stage and showed that smoking
ignificantly increases the risk of detecting a tumor regardless of its
ize. Recently, Carpenter [17] found that there was no significant
ifference in the tumor stage and grade in smokers but reported
hat recurrence was significantly higher. Su et al. [18] reported that
umors smaller than 3 cm tend to have a lower grade and stage than












[20] vanRoekel EH, Cheng KK, James ND, Wallace DM, Billingham LJ,
Murray PG, et al. Smoking is associated with lower age, higher grade,Effect of smoking on pathological grade and stage in clinically 
size in both groups was smaller than 3 cm, it was found that high
grade and stage tumors were more prevalent in the smoker group.
These findings suggest that smoking increases the stage and grade
of the tumor regardless of its size.
The risk of developing bladder cancer is directly related to the dura-
tion and intensity of cigarette smoking [19]. In a study showing the
relationship between smoking and bladder cancer stages and grades,
it was reported that active smokers have higher grades and stages
of bladder cancer when compared to those who have never smoked
and have quit smoking. Additionally, those who have quit smoking
have higher stages and grades than those who never smoked. The
duration of smoking and quitting cigarette smoking affects the risk
of bladder cancer [20].
There are some limitations in the present study. The retrospective
nature was the main limitation of the study. Additionally, the dura-
tion of smoking was not investigated due to the retrospective design
of the study. The small number of patients and the small number of
enrolled women are some other limitations of this study. Although
there are several limitations mentioned, we believe that the findings
are clinically useful.
Conclusions
Under the light of the data, smoking seems to be associated with
worse pathological features (tumor stage, tumor grade) in patients
with primary, single, <3 cm, non-muscle-invasive bladder cancer.
Despite the limitations of our study, we find this finding clinically
useful.
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